Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PfizerfiledCriticalPfizer
Priority to DO2002000514ApriorityCriticalpatent/DOP2002000514A/en
Publication of DOP2002000514ApublicationCriticalpatent/DOP2002000514A/en
208000023504respiratory system diseaseDiseases0.000abstract1
Landscapes
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
La presente invención se refiere a una combinación que comprende (a) un agonista del receptor de adenosina A2a como se define en la presente memoria y (b) un agonista del receptor (B2-adrenergico, para la administración simultánea, secuencial o por separado por vía inhalada en el tratamiento de una enfermedad obstructiva de las vías respiratorias u otra enfermedad inflamatoria.The present invention relates to a combination comprising (a) an adenosine A2a receptor agonist as defined herein and (b) a receptor agonist (B2-adrenergic), for simultaneous, sequential or separate administration by Inhaled route in the treatment of an obstructive airway disease or other inflammatory disease.
Pharmaceutical composition comprising immunosuppressants to improve the effect in the use of an antagonist of interleukin-6 (il-6) for the treatment of illnesses related to il-6 (div. Sol. 896-04).
use of a human interleukin-2 mutein (hil-2 mutein) or a fragment thereof, pharmaceutical composition for the treatment and / or prophylaxis of an autoimmune disease, use of human interleukin-2 mutein (hil-2 mutein) 2) or a section thereof, for the formation of regulatory t cells (treg) in an organism, method for treatment and / or prophylaxis of an autoimmune disease in an organism, method for formation of regulatory t cells (treg) in an organism organism, method for formation of regulatory t cells (treg) in vitro.
Pharmaceutical composition covered by a film comprising capecitabine and at least one disintegrant, useful in the treatment of cancer for patients who have difficulty swallowing oral solid dosage forms.